Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Almirall Knocked Back By US Woes, Could Affect Other Companies Too

Executive Summary

Spain’s Almirall has suffered business setbacks in the US - including in its patient assistance program - that have forced the mid-sized drug maker to issue a profit warning, triggering of a sharp slide in its share price.

Advertisement

Related Content

Interview: Almirall CEO Guenter Plots 'Play To Win' Future
Almirall To Put More Skin In The Game With Derma Buys
Guenter Stays Focused After Almirall's Annus Horribilis
Spanish Biotech Star Oryzon Slumps After Roche Rejection
Almirall Eyes Top Specialty Dermatology Role After its AstraZeneca Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel